Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-24T00:19:22.591Z Has data issue: false hasContentIssue false

Patent ductus arteriosus in preterm infants born before 30 weeks’ gestation: high rate of spontaneous closure after hospital discharge

Published online by Cambridge University Press:  29 June 2018

Vittorio Romagnoli*
Affiliation:
Department of Pediatrics, Presidio Ospedaliero G Salesi, Ancona, Marche, Italy
Annalisa Pedini
Affiliation:
Department of Pediatrics, Ospedale degli Infermi, Rimini, Emilia-Romagna, Italy
Monica Santoni
Affiliation:
Department of Neonatology, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Marche, Italy
Grazia Scutti
Affiliation:
Department of Neonatology, Presidio Ospedaliero G Salesi, Ancona, Marche, Italy
Massimo Colaneri
Affiliation:
Department of Paediatric and Congenital Cardiac Surgery and Cardiology, Ospedali Riuniti di Ancona, Ancona, Marche, Italy
Marco Pozzi
Affiliation:
Department of Paediatric and Congenital Cardiac Surgery and Cardiology, Ospedali Riuniti di Ancona, Ancona, Marche, Italy
Paola E. Cogo
Affiliation:
Department of Pediatrics, Università degli Studi di Udine Polo Medico Medicina e Chirurgia, Udine, Friuli-Venezia Giulia, Italy
Virgilio P. Carnielli
Affiliation:
Department of Neonatology, Università Politecnica delle Marche, Ancona, Marche, Italy
*
Author for correspondence: V. Romagnoli, MD, Department of Pediatrics, Presidio Ospedaliero G Salesi, Via Corridoni, 11, 60123, Ancona, Marche, Italy. Tel: +39 71 596 2234; Fax: +39 71 596 2530; E-mail: [email protected]

Abstract

Aim

The aim of this study was to determine the spontaneous closure rate of patent ductus arteriosus at a 2-year follow-up, following failed medical therapy and beyond initial hospital discharge, and to evaluate in-hospital spontaneous or pharmacological closure rates.

Materials and methods

A retrospective evaluation was conducted in a cohort of preterm infants admitted to the Neonatal ICU of Ancona between January, 2004 and June, 2013. Inclusion criteria were gestational age between 24+0 and 29+6 weeks or birth weight <1250 g; admission within 48 hours from birth; and discharge alive from hospital. All infants received routine heart ultrasound between 48 and 72 hours of life. Haemodynamically significant patent ductus arteriosus was defined as a duct diameter >1.5 mm, a left atrium-to-aorta ratio >1.4, and/or reversal of end-diastolic flow in the aorta >30% of the anterograde. First-line treatment was intravenous ibuprofen. Intravenous indomethacin was used if ibuprofen failed. Surgical ligation was considered in haemodynamically significant patent ductus arteriosus after medical treatment.

Results

A total of 593 infants met the inclusion criteria, and patent ductus arteriosus was diagnosed in 317 (53.4%). Among them, 283 (89.3%) infants had haemodynamically significant patent ductus arteriosus, with pharmacological closure achieved in 228 (80.6%) infants and surgical ligation performed in 20 (7.1%). Follow-up at 24 months was available for 39 (81.3%) of 48 infants with patent ductus arteriosus at the hospital discharge: 36 (92.3%) underwent spontaneous closure, two (5.1%) underwent surgical ligation, and one (2.6%) had a patent ductus arteriosus.

Discussion

A significant number of patent ductus arteriosus that fail pharmacological closure undergo spontaneous closure by the age of 2 years. This information should be taken into account when considering surgery or additional attempts of pharmacological closure.

Type
Original Article
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Cite this article: Romagnoli V, Pedini A, Santoni M, Scutti G, Colaneri M, Pozzi M, Cogo PE, Carnielli VP. (2018) Patent ductus arteriosus in preterm infants born before 30 weeks’ gestation: high rate of spontaneous closure after hospital discharge. Cardiology in the Young28: 995–1000. doi: 10.1017/S1047951118000641

References

1. Hajj, H, Dagle, JM. Genetics of patent ductus arteriosus susceptibility and treatment. Semin Perinatol 2012; 36: 98104.Google Scholar
2. Clyman, RI, Couto, J, Murphy, GM. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? Semin Perinatol 2012; 36: 123129.Google Scholar
3. Cooke, L, Steer, P, Woodgate, P. Indomethacin for asymptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev 2003; 2: CD003745.Google Scholar
4. Reese, J. Patent ductus arteriosus: mechanisms and management. Semin Perinatol 2012; 36: 8991.Google Scholar
5. Mitra, S, Rønnestad, A, Holmstrøm, H. Management of patent ductus arteriosus in preterm infants: where do we stand? Congenit Heart Dis 2013; 8: 500512.Google Scholar
6. Herrman, K, Bose, C, Lewis, K, Laughon, M. Spontaneous closure of the patent ductus arteriosus in very low birth weight infants following discharge from the neonatal unit. Arch Dis Child Fetal Neonatal Ed 2009; 94: F48F50.Google Scholar
7. Lai, WW, Geva, T, Shirali, GS, et al. Guidelines and standards for performance of a pediatric echocardiogram: a report from the Task Force of the Pediatric Council of the American Society of Echocardiography. J Am Soc Echocardiogr 2006; 19: 14131430.CrossRefGoogle ScholarPubMed
8. Benitz, WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol 2010; 30: 241252.Google Scholar
9. Van Overmeire, B. Patent ductus arteriosus: how aggressive should we be? Neonatology 2007; 138: 205211.Google Scholar
10. Horbar, JD. The Vermont-Oxford Neonatal Network: integrating research and clinical practice to improve the quality of medical care. Semin Perinatol 1995; 19: 124131.Google Scholar
11. Sellmer, A, Bjerre, JV, Schmidt, MR, et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Arch Dis Child Fetal Neonatal Ed 2013; 98: F505F510.CrossRefGoogle ScholarPubMed
12. Gokmen, T, Erdeve, O, Altug, N, Oguz, SS, Uras, N, Dilmen, U. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J Pediatr 2011; 158: 549554.CrossRefGoogle ScholarPubMed
13. Bagnoli, F, Rossetti, A, Messina, G, Mori, A, Casucci, M, Tomasini, B. Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. J Matern Fetal Neonatal Med 2013; 26: 423429.CrossRefGoogle ScholarPubMed
14. Van Der Lugt, NM, Lopriore, E, Bökenkamp, R, Smits-Wintjens, VE, Steggerda, SJ, Walther, FJ. Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus. Eur J Pediatr 2012; 171: 16731677.Google Scholar
15. Richards, J, Johnson, A, Fox, G, Campbell, M. A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics 2009; 124: 287293.CrossRefGoogle ScholarPubMed
16. Vida, VL, Lago, P, Salvatori, S, et al. Is there an optimal timing for surgical ligation of patent ductus arteriosus in preterm infants? Ann Thorac Surg 2009; 87: 15091516.CrossRefGoogle ScholarPubMed
17. Lemmers, PM, Toet, MC, van Bel, F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. Pediatrics 2008; 121: 142147.Google Scholar
18. Van Overmeire, B, Van de Broek, H, Van Laer, P, Weyler, J, Vanhaesebrouck, P. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 2001; 138: 205211.CrossRefGoogle ScholarPubMed
19. Sangem, M, Asthana, S, Amin, S. Multiple courses of indomethacin and neonatal outcomes in premature infants. Pediatr Cardiol 2008; 29: 878884.CrossRefGoogle ScholarPubMed
20. Hammerman, C, Shchors, I, Jacobson, S, et al. Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: Is the difference in the mode of administration? Pediatr Res 2008; 64: 291297.CrossRefGoogle ScholarPubMed
21. Gudmundsdottir, A, Johansson, S, Håkansson, S, Norman, M, Källen, K, Bonamy, AK. Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants. Neonatology 2014; 107: 8792.Google Scholar
22. Sivanandan, S, Bali, V, Soraisham, AS, Harabor, A, Kamaluddeen, M. Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants. Am J Perinatol 2013; 30: 745750.Google Scholar
23. Sosenko, IR, Fajardo, MF, Claure, N, Bancalari, E. Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. J Pediatr 2012; 160: 929935.Google Scholar
24. Weber, SC, Weiss, K, Buhrer, C, Hansmann, G, Koehne, P, Sallmon, H. Natural history of patent ductus arteriosus in very low birth weight infants after discharge. J Pediatr 2015; 167: 11491151.CrossRefGoogle ScholarPubMed
25. Bancalari, E, Claure, N, Gonzalez, A. Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate 2005; 88: 192201.Google Scholar
26. Clyman, RI. The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia. Semin Perinatol 2013; 37: 102107.Google Scholar
27. Feltes, TF, Bacha, E, Beekman, RH, et al. Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association. Circulation 2011; 123: 26072652.Google Scholar
28. Hammerman, C, Bin-Nun, A, Kaplan, M. Managing the patent ductus arteriosus in the premature neonate: a new look at what we thought we knew. Semin Perinatol 2012; 36: 130138.CrossRefGoogle Scholar